These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 19293270

  • 1. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly.
    Neto LV, Machado Ede O, Luque RM, Taboada GF, Marcondes JB, Chimelli LM, Quintella LP, Niemeyer P, de Carvalho DP, Kineman RD, Gadelha MR.
    J Clin Endocrinol Metab; 2009 Jun; 94(6):1931-7. PubMed ID: 19293270
    [Abstract] [Full Text] [Related]

  • 2. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas.
    Taboada GF, Luque RM, Bastos W, Guimarães RF, Marcondes JB, Chimelli LM, Fontes R, Mata PJ, Filho PN, Carvalho DP, Kineman RD, Gadelha MR.
    Eur J Endocrinol; 2007 Jan; 156(1):65-74. PubMed ID: 17218727
    [Abstract] [Full Text] [Related]

  • 3. ZAC1 and SSTR2 are downregulated in non-functioning pituitary adenomas but not in somatotropinomas.
    Vieria Neto L, Wildemberg LE, Colli LM, Kasuki L, Marques NV, Moraes AB, Gasparetto EL, Takiya CM, Castro M, Gadelha MR.
    PLoS One; 2013 Jan; 8(10):e77406. PubMed ID: 24098585
    [Abstract] [Full Text] [Related]

  • 4. Impact of gsp oncogene on the mRNA content for somatostatin and dopamine receptors in human somatotropinomas.
    Taboada GF, Neto LV, Luque RM, Córdoba-Chacón J, de Oliveira Machado E, de Carvalho DP, Kineman RD, Gadelha MR.
    Neuroendocrinology; 2011 Jan; 93(1):40-7. PubMed ID: 21079388
    [Abstract] [Full Text] [Related]

  • 5. Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro.
    Zatelli MC, Piccin D, Tagliati F, Bottoni A, Ambrosio MR, Margutti A, Scanarini M, Bondanelli M, Culler MD, degli Uberti EC.
    J Mol Endocrinol; 2005 Oct; 35(2):333-41. PubMed ID: 16216913
    [Abstract] [Full Text] [Related]

  • 6. Genetic abnormalities of somatostatin receptors in pituitary tumors.
    Lania A, Mantovani G, Spada A.
    Mol Cell Endocrinol; 2008 May 14; 286(1-2):180-6. PubMed ID: 17913341
    [Abstract] [Full Text] [Related]

  • 7. Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs.
    Wildemberg LE, Neto LV, Costa DF, Nasciuti LE, Takiya CM, Alves LM, Rebora A, Minuto F, Ferone D, Gadelha MR.
    J Endocrinol Invest; 2013 Jan 14; 36(1):38-43. PubMed ID: 22472799
    [Abstract] [Full Text] [Related]

  • 8. Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles.
    Coelho MCA, Vasquez ML, Wildemberg LE, Vázquez-Borrego MC, Bitana L, Camacho AHDS, Silva D, Ogino LL, Ventura N, Sánchez-Sánchez R, Chimelli L, Kasuki L, Luque RM, Gadelha MR.
    Sci Rep; 2019 Feb 04; 9(1):1122. PubMed ID: 30718563
    [Abstract] [Full Text] [Related]

  • 9. Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas.
    Luque RM, Ibáñez-Costa A, Neto LV, Taboada GF, Hormaechea-Agulla D, Kasuki L, Venegas-Moreno E, Moreno-Carazo A, Gálvez MÁ, Soto-Moreno A, Kineman RD, Culler MD, Gahete MD, Gadelha MR, Castaño JP.
    Cancer Lett; 2015 Apr 10; 359(2):299-306. PubMed ID: 25637790
    [Abstract] [Full Text] [Related]

  • 10. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
    Horiguchi K, Yamada M, Umezawa R, Satoh T, Hashimoto K, Tosaka M, Yamada S, Mori M.
    Endocr J; 2007 Jun 10; 54(3):371-8. PubMed ID: 17420609
    [Abstract] [Full Text] [Related]

  • 11. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR.
    Taboada GF, Luque RM, Neto LV, Machado Ede O, Sbaffi BC, Domingues RC, Marcondes JB, Chimelli LM, Fontes R, Niemeyer P, de Carvalho DP, Kineman RD, Gadelha MR.
    Eur J Endocrinol; 2008 Mar 10; 158(3):295-303. PubMed ID: 18299461
    [Abstract] [Full Text] [Related]

  • 12. Somatostatin receptors subtypes 2 and 5, dopamine receptor type 2 expression and gsp status as predictors of octreotide LAR responsiveness in acromegaly.
    Vieira Neto L, Taboada GF, Gadelha MR.
    Arq Bras Endocrinol Metabol; 2008 Nov 10; 52(8):1288-95. PubMed ID: 19169483
    [Abstract] [Full Text] [Related]

  • 13. Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide.
    Park C, Yang I, Woo J, Kim S, Kim J, Kim Y, Sohn S, Kim E, Lee M, Park H, Jung J, Park S.
    Endocr J; 2004 Apr 10; 51(2):227-36. PubMed ID: 15118275
    [Abstract] [Full Text] [Related]

  • 14. Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues--Observations in two patients with acromegaly and severe headache.
    Marina D, Burman P, Klose M, Casar-Borota O, Luque RM, Castaño JP, Feldt-Rasmussen U.
    Growth Horm IGF Res; 2015 Oct 10; 25(5):262-7. PubMed ID: 26188991
    [Abstract] [Full Text] [Related]

  • 15. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
    Ibáñez-Costa A, Rivero-Cortés E, Vázquez-Borrego MC, Gahete MD, Jiménez-Reina L, Venegas-Moreno E, de la Riva A, Arráez MÁ, González-Molero I, Schmid HA, Maraver-Selfa S, Gavilán-Villarejo I, García-Arnés JA, Japón MA, Soto-Moreno A, Gálvez MA, Luque RM, Castaño JP.
    J Endocrinol; 2016 Nov 10; 231(2):135-145. PubMed ID: 27587848
    [Abstract] [Full Text] [Related]

  • 16. AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression.
    Kasuki L, Vieira Neto L, Wildemberg LE, Colli LM, de Castro M, Takiya CM, Gadelha MR.
    Endocr Relat Cancer; 2012 Jun 10; 19(3):L25-9. PubMed ID: 22420004
    [No Abstract] [Full Text] [Related]

  • 17. Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly.
    Venegas-Moreno E, Vazquez-Borrego MC, Dios E, Gros-Herguido N, Flores-Martinez A, Rivero-Cortés E, Madrazo-Atutxa A, Japón MA, Luque RM, Castaño JP, Cano DA, Soto-Moreno A.
    J Cell Mol Med; 2018 Mar 10; 22(3):1640-1649. PubMed ID: 29266696
    [Abstract] [Full Text] [Related]

  • 18. Cytoplasmic expression of SSTR2 and 5 by immunohistochemistry and by RT/PCR is not associated with the pharmacological response to octreotide.
    Gonzalez B, Vargas G, Ramirez C, Asa S, Cheng S, Sandoval C, Mercado M.
    Endocrinol Nutr; 2014 Dec 10; 61(10):523-30. PubMed ID: 25008035
    [Abstract] [Full Text] [Related]

  • 19. Growth hormone isoforms in acromegalic patients before and after treatment with octreotide LAR.
    Lima GA, Wu Z, Silva CM, Barbosa FR, Dias JS, Schrank Y, Strasburger CJ, Gadelha MR.
    Growth Horm IGF Res; 2010 Apr 10; 20(2):87-92. PubMed ID: 19884028
    [Abstract] [Full Text] [Related]

  • 20. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
    Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD.
    Clin Endocrinol (Oxf); 2007 Aug 10; 67(2):310-5. PubMed ID: 17555503
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.